Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVAIL-T
2016-004879-46Phase 2Unknown
- Sponsor
- University of Birmingham
- Start
- May 2018
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of avelumab in peripheral T-cell lymphoma (PTCL) and adult T-cell leukemia-lymphoma (ATLL), sponsored by University of Birmingham. Primary endpoint: Best overall response. Status: unknown.
02
Drugs
avelumab
03
Conditions
peripheral T-cell lymphoma (PTCL)adult T-cell leukemia-lymphoma (ATLL)
Beyond the preview
Go deeper on 2016-004879-46.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004879-46.